ReviewJournal of clinical medicine2022
Non-Tuberculous Mycobacteria and
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Clinical impact of chronic pulmonary aspergillosis in patients with pulmonary nontuberculous mycobacterial disease and colonization: a multicentre prospective cohort study.Annals of medicine · 2026Article
- Fungal-Associated Endotypes as a Treatable Trait in Bronchiectasis.Pulmonary therapy · 2026Review
- Non-tuberculous mycobacteria (NTM) and COPD: a multicentre prospective study.BMJ open respiratory research · 2025Observational
- Article
- Distinct lung microbiota community states are associated with pulmonary nontuberculous mycobacterial disease prognosis.BMC microbiology · 2025Article
- Article
- Negligible clinical impact of subsequent non-tuberculous mycobacteria isolation during MDR/RR-TB treatment: a 9-year retrospective cohort study from Wenzhou, China.BMC infectious diseases · 2025Article
- Observational
- Lung Microenvironment Among Patients with Nontuberculous Mycobacterial Pulmonary Disease by Metagenomic Sequencing Technique.Biomedicines · 2025Article
- The Advance and Clinical Practice on Lung Disease Caused byInfection and drug resistance · 2025Article
- Pathogen spectrum and management strategies for opportunistic infections in lung cancer in the immunotherapy era: recent advances from fungi to mycobacteria.American journal of cancer research · 2025Review
- Diagnostic Significance of Hematological Parameters and Ratios in the Context ofInfection and drug resistance · 2025Article
- Esophageal hyperkeratosis in a teenager with asthma and chronic cough complicated by nontuberculous mycobacteria pulmonary infection.SAGE open medical case reports · 2025Article
- Identification of prognostic factors of chronic pulmonary aspergillosis: a retrospective cohort of 106 patients.Journal of thoracic disease · 2024Article
- The Association of Chronic Pulmonary Aspergillosis and Chronic Pulmonary Histoplasmosis with MDR-TB Patients in Indonesia.Journal of fungi (Basel, Switzerland) · 2024Article
- Treatable traits and challenges in the clinical management of non-tuberculous mycobacteria lung disease in people with cystic fibrosis.Respiratory research · 2023Review
- Lady Windermere syndrome with haemoptysis: suspected pulmonary aspergilloma and MAC pulmonary disease.BMJ case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-tuberculous mycobacteria (NTM) and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.